Core Viewpoint - A class action lawsuit has been filed against DeFi Technologies, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from May 12, 2025, to November 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased DeFi Technologies securities during the specified Class Period [2]. - The Complaint alleges that Defendants made false and misleading statements and failed to disclose critical issues affecting the company, including delays in executing its DeFi arbitrage strategy, competition from other digital asset treasury companies, and an inability to meet revenue guidance for fiscal year 2025 [3]. Group 2: Implications for Investors - Investors are encouraged to join the class action and can request to be appointed as lead plaintiff until January 30, 2026 [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

What Is the Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Jayud was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) that inside ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from April 1, 2024, to December 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Vistagen securities during the specified Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements regarding the development of fasedienol and the Phase 3 PALISADE‑3 trial, which faced significant adverse facts [3]. - Defendants are accused of disseminating false information and concealing material adverse data about the PALISADE‑3 study's design, execution, and clinical results [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by March 16, 2026, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - The exchange is pursuing regulatory approval for a "tokenized securities platform," which aims to innovate the way securities are issued and traded [1] Group 1 - The platform is designed to enhance liquidity and accessibility in the securities market [1] - It represents a shift towards digital assets, aligning with broader trends in financial technology [1] - The initiative could potentially attract a new class of investors who are interested in tokenized assets [1]

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol, leading to inflated stock prices during the class period from April 1, 2024, to December 16, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen's defendants made positive assertions about the success of fasedienol based on prior clinical trial results, which misled investors [5]. - It is alleged that while promoting fasedienol's potential, the defendants concealed material adverse facts about the Phase 3 PALISADE-3 trial, resulting in shareholders purchasing stock at artificially inflated prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7].

Total disclosed value for deals in 2025 “rose significantly” to $418.9 billion from $282.1 billion a year prior. This included 93 deals valued at more than $1 billion, which accounted for 81% of total deal value last year. By comparison, 54 such deals were announced in 2024.“Market conditions continued to challenge global financial services dealmaking in 2025 but did not dampen investment appetite within the sector. While the number of deals was only up marginally year-on-year, overall value was up 49%. Tra ...

Group 1 - The Income Compounder Portfolio utilizes an Income Factory strategy focused on compounding investment income through reinvesting and increasing the share count of dividend-paying securities, which aids in generating a growing income stream over time, independent of market conditions [1] Group 2 - The investor profile described is income-oriented, seeking high-yield income to support retirement lifestyle, with a focus on dividend-paying stocks and funds such as BDCs, REITs, CEFs, and ETFs to enhance retirement income beyond pension and Social Security [2] - The investor emphasizes the importance of conducting thorough research and making informed long-term investment decisions, particularly after experiencing minimal losses during the Great Recession [2]

Key Points Ripple still controls over a third of the 100 billion XRP tokens it minted at launch, though some are in escrow. Ripple has ambitious plans to combine blockchain with traditional finance, but XRP may not benefit if it succeeds. XRP's market cap would put it among the top 100 U.S. firms, which seems hard to sustain. 10 stocks we like better than XRP › Ripple's XRP (CRYPTO: XRP) was one of last year's biggest crypto stories of last year. On July 18, 2024, it was worth just under $0.60. ...

Bitcoin has fallen for a fifth straight session, pulling back from its highest levels since November as it struggles to hold above the $92,000 mark. Key Takeaways: Bitcoin has slid for a fifth straight day on profit-taking and rising political and macro uncertainty. The pullback remains orderly, with low liquidations, falling leverage, and renewed spot ETF and whale demand. Ongoing concerns over Federal Reserve independence are reinforcing risk-off sentiment. According to Samer Hasn, senior marke ...

Group 1 - Samos Energy has signed a ship sale agreement to acquire the Suksan Salamander floating storage and offloading (FSO) unit from Altera Infrastructure Group, with financial terms undisclosed [1] - The Suksan Salamander FSO is currently operational at the Bualuang oilfield offshore Thailand, managed by Medco Energi Thailand [1][4] - The FSO has a capacity of 78,228 deadweight tonnes (dwt) and can store approximately 470,000 barrels of crude oil, processing and offloading at a rate of 20,000 barrels per day (bpd) [2][5] Group 2 - The acquisition is part of Samos Energy's strategy to enhance its offshore production asset portfolio, complementing existing assets in Southeast Asia, including three floating production units acquired from BlackRock in 2023 [3] - Samos Energy has partnered with FPSO Ventures for the operations and maintenance of the Suksan Salamander FSO, ensuring operational efficiency and safety standards for Medco Energi Thailand [3][4] - The company is actively securing new equity and debt facilities to facilitate further expansion of its offshore production fleet and to acquire new exploration, production, midstream, and power platforms [3][4]